Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Joe Kiani

Can We Fix Political Conversation Online? Joe Kiani's CitizeX Is Betting on Identity Verification, Not Algorithms

CitizeX positions itself as a verified civic engagement platform designed to foster bipartisan, human-centered dialogue. Its approach is simple but meaningful.

International Business Times

What Entrepreneur and Innovator Joe Kiani Has Been Up to One Year After His Masimo Resignation

In over three decades, Joe Kiani led Masimo from a California startup into a global leader in patient monitoring. Since his resignation in late 2024, Kiani has not slowed down but rather redirected his energy into a series of ventures that combine health, technology, and human connection.

Medical Daily

Joe Kiani and the Rise of Preventative Healthcare Tech: A New Frontier in Medicine

In a world where healthcare expenditures continue to skyrocket and chronic illnesses burden national economies, a quiet revolution is taking place in the medical technology space. One visionary leading this transformation is Joe Kiani, the entrepreneur behind Masimo and now the founder of Willow Laboratories.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Joe Kiani's Post-Masimo Playbook: Innovation Without Borders

For Kiani, entrepreneurship has never been merely about building companies; it has been about solving pressing problems with persistence and vision.

International Business Times

Joe Kiani is back: After being ousted from Masimo the billionaire has returned as CEO of Like Minded Labs

Also: All the news and watercooler chat from Fortune.

Fortune

How Immigrant Engineer and Entrepreneur Joe Kiani Reimagined Inclusion in Tech and Medicine

As founder of Masimo and the force behind Willow Laboratories, Kiani has contributed to life-saving innovations in patient monitoring and wellness.

International Business Times

Putting Patients First with Joe Kiani: Why Safety Must Be the Heart of Modern Healthcare

With medical errors still claiming hundreds of thousands of lives annually, Joe Kiani's Patient Safety Movement Foundation is pushing for bold, systemic change to put patient safety at the core of modern medicine.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

Masimo founder Joe Kiani vs. activist Politan Capital: A two-year battle comes to a head this week

Founder Joe Kiani has led Masimo for 35 years. But he says he'll quit if he loses this week's proxy vote to Politan Capital.

Fortune

Chris Evans to receive Spirit of Service award for helping ‘build more civically engaged society’

Actor will receive award for starting civic engagement platform along with Mark Kassen and Joe Kiani

The Independent UK

Apple's patent rival claims the Apple Watch's blood oxygen feature is unreliable

Masimo CEO Joe Kiani has made some controversial comments about Apple's tech in a Bloomberg interview.

TechRadar

Masimo CEO claims the Apple Watch Blood Oxygen sensors are inaccurate — and that users will be "better off" without them

The Masimo VS Apple battle continues as Masimo CEO Joe Kiani continues to give interviews as proceedings are still ongoing.

iMore

Apple Watch ban latest – the Watch 9 and Ultra 2 could go off sale again soon

Apple is seeking to end the pause on its wearable, but new opposition from the ITC could be the final nail in the coffin.

TechRadar

“It’s painful. It’s an ugly thing to go through. It’s like war” – Masimo CEO talks about his legal battle with Apple which halted the sale of current Apple Watches

Joe Kiani, Masimo CEO, was recently interviewed on his legal battle with Apple, disputing their Blood Oxygen technology.

iMore

Apple's Watch ban could be a $400 million mistake — Masimo patent dispute could cost the company big in holiday sales

Apple's decision to withdraw the Apple Watch Series 9 and Ultra 2 from sale could cost it $400 million this holiday season.

iMore

Get all your
news in one place.

100's of premium titles.
One news app.

iMore

Apple Watch ban could be avoided if only Apple was willing to talk, owner of the tech at the heart of a long-running patent battle hints — but its CEO isn't optimistic

The CEO of Masimo, the company that owns a patent Apple is accused of infringing, says he'd be willing to discuss a settlement — but Apple seems uninterested.

Tribune News Service

Hillary Clinton talks drug addiction, overdose rescue kits in Las Vegas

LAS VEGAS — Robert Banghart’s life was saved by naloxone twice in one evening when he overdosed from heroin.

Fortune

Shareholder activism's rise comes with more failures

Experts say it's not a sign of an ESG backlash.

Benzinga

Masimo Posts Better Than Expected Q1 Earnings Despite 'Unexpected' Supply Chain Issues

Masimo Corp's (NASDAQ:MASI) Q1 revenue increased 1.7% Y/Y (+3.2% on a constant currency basis) to $304.2 million, beating the consensus of $303.83 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 75,700 in Q1 of 2022. The adjusted operating margin remained unchanged at 22.9%. The company reported…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Supply Chain Challenges To Hit Masimo's Q1 FY22 Sales

Masimo Corp (NASDAQ:MASI) expects Q1 FY22 product revenue of $285 million - $315 million, lower than expected. Shortages of critical components and other supply chain issues, including freight carrier delays, have led to lower-than-expected sales in the first quarter. Related: Joe Kiani, Chairman, and CEO, said, "In prior quarters, we were able…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

San Diego State University

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.